FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – February 2026 Published

FCF Fox Corporate Finance GmbH is pleased to publish the new "FCF Healthcare & Life Sciences Venture Capital Monitor - Europe 02/2026".

The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe is a monthly overview of financing trends in the venture capital sector with a focus on European healthcare & life sciences companies.

As of the end of February 2026, we identified the following current VC trends in Europe:

• Total Healthcare & Life Sciences funding reached EUR 1,456m (-51% vs. 2025), which represents about half of the volume of the same period in 2025
• Biotech/Pharma received 40% of the total investment volume (EUR 576m), with ophthalmology being the leading indication (47%)
• In February, Immutrin (United Kingdom) secured the highest transaction volume with EUR 75m, followed by NEUROMARK (United States) with EUR 63m and Dawn Health (Denmark) with EUR 33m
• EQT Life Sciences (Netherlands) is the most active investor (by deal volume in 2026), followed by F-Prime Capital (United States) and Sofinnova Partners (France)

So far in 2026, we see fewer large-ticket deals, which explains the steep decline in funding volume. We are only two months into 2026, so the market could still recover.

To read the full report, click here.